8-K current report · filed Aug 6, 2026

PepGen Inc (PEPG) 8-K Current Report: August 6, 2026

Item 2.02Item 7.01Item 8.01Item EX-99.1Item EX-99.2Item EX-99.3PEPG overview

Short answer

PepGen Inc (PEPG) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). PepGen announced second-quarter 2026 financial results for the quarter ended June 30, 2026.

PepGen Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • PepGen announced second-quarter 2026 financial results for the quarter ended June 30, 2026
  • Press release also covers recent corporate highlights, providing investors operational updates beyond financial results
  • Full financial figures and business details appear in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation reflects PepGen’s recent corporate updates as of August 6, 2026
  • Exhibit 99.2 contains the presentation, potentially including updated strategic, clinical, or financial information

Item 8.01 · Other Events

  • DSMB cleared FREEDOM2-DM1’s highest MAD cohort, advancing dosing to 12.5 mg/kg
  • No protocol changes recommended, supporting continued execution of the Phase 2 study
  • OLE dosing escalation approved from 5 mg/kg to 10 mg/kg
  • Safety review supports PepGen’s ongoing clinical development path in DM1

Item EX-99.1 · Exhibit EX-99.1

  • DSMB-cleared escalation to 12.5 mg/kg, supporting continued clinical development of PGN-EDODM1 in DM1
  • 10 mg/kg cohort fully enrolled, with 7 of 8 participants dosed; data expected November 2026
  • 12.5 mg/kg results expected 1H 2027, potential basis for end-of-Phase 2 regulatory discussions
  • Cash $117.2M, projected funding through 4Q 2027, reducing near-term financing risk
  • Net loss $17.8M, or $0.26 per share, versus $23.1M, or $0.70 per share, in 2Q 2025

Item EX-99.2 · Exhibit EX-99.2

  • PGN-EDODM1 showed dose-dependent single-dose splicing correction, reaching 53.7% mean improvement at 15 mg/kg and 83% of patients exceeding 20% correction
  • FREEDOM2 5 mg/kg repeat dosing produced 22.9% mean splicing correction excluding one outlier, with promising vHOT myotonia trends
  • 5 mg/kg FREEDOM2 safety remained favorable: all 8 participants completed dosing, with no serious adverse events, dose-limiting toxicities, or cumulative toxicity
  • FDA partial clinical hold remains a regulatory overhang, while FREEDOM2 is cleared in South Korea, Australia, and New Zealand
  • Upcoming catalysts: November 10 mg/kg results, early January OLE update, and 1H 2027 12.5 mg/kg results, with cash runway into 4Q 2027

Item EX-99.3 · Exhibit EX-99.3

  • DSMB cleared PGN-EDODM1 advancement to the highest planned 12.5 mg/kg cohort in Phase 2 FREEDOM2-DM1
  • Safety review found no serious adverse events, dose-limiting toxicities, cumulative toxicity, or treatment discontinuations
  • OLE dose escalation from 5 mg/kg to 10 mg/kg, with 16 participants enrolled and 6 of 8 5 mg/kg participants opting in
  • 10 mg/kg FREEDOM2 results expected in November, supporting the next near-term clinical catalyst
  • 12.5 mg/kg results expected in the first half of 2027, followed by planned end-of-Phase-2 regulatory discussions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PepGen Inc 8-K filings

Get the next PEPG 8-K as it lands

Follow PEPG for push alerts, or ask the research agent what this filing means.